SIRIUS-SLE LTENCT06133972
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
At risk: Primary completion moved at least 3 years 11 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 34 versions: 33 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Study sites: 162 to 164
Notable Primary completion pushed from Apr 8, 2030 to Apr 3, 2034 Show 6 more changesShow less
- Primary endpoints: details revised at 1 of 1 entry
- Trial sites expanded: 143 → 162 locations
- Study completion pushed from Apr 5, 2032 to Oct 2, 2034
- Eligibility criteria shortened, about 65 words
- Secondary endpoints: 4 to 7
- Study description expanded, about 67 words
- Minor Trial sites expanded: 127 → 143 locationsv32
- Minor Study sites: 113 to 127
- Primary completion date: Apr 19, 2030 to Apr 8, 2030
- Study completion date: Apr 16, 2032 to Apr 5, 2032
- Minor Study sites: 109 to 113v30
Show 27 earlier versionsHide 27 earlier versions
- Minor Study sites: 103 to 109v29
- Minor Study sites: 100 to 103v28
- Minor Study sites: 79 to 100v27
- Minor Study sites: 71 to 79
- Primary completion date: Dec 25, 2029 to Apr 19, 2030
- Study completion date: Dec 23, 2031 to Apr 16, 2032
- Minor Study sites: 70 to 71v25
- Minor Study sites: 62 to 70v24
- Minor Study sites: 48 to 62v23
- Minor Study sites: 42 to 48v22
- Minor Study sites: 35 to 42v21
- Minor Study sites: 22 to 35v20
- Minor Study sites: 21 to 22v19
- Minor Study sites: 18 to 21v18
- Minor Study sites: 17 to 18v17
- Minor Study sites: 15 to 17v16
- Minor Study sites: 14 to 15v15
- Minor Study sites: 12 to 14v14
- Minor Study sites: 11 to 12v13
- Minor Study sites: 10 to 11v12
- Minor Study sites: 8 to 10v10
- Minor Study sites: 7 to 8v9
- Minor Study sites: 5 to 7v8
- Minor Study sites: 4 to 5v7
- Minor Study sites: 3 to 4v6
- Minor Study sites: 1 to 3v5
- Minor Study sites: 2 to 1v4
- Minor Study sites: 1 to 2v3
Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
- Primary completion date: Dec 9, 2031 to Dec 25, 2029
- Study sites: 0 to 1
- Study completion date: Dec 9, 2031 to Dec 23, 2031
- Start date: May 17, 2024 to May 21, 2024
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Number of treatment-emergent Adverse events/Serious Adverse events
Timeframe: through study completion, up to approximately 324 weeks
Secondary (7)
Proportion of participants who achieved Systemic Lupus Erythematosus Responder Index -4 (SRI-4) response
Proportion of participants who achieved Definition of Remission in SLE (DORIS) response
Change in Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index
Average daily dose of corticosteroids administered
Annualized BILAG moderate or severe flare rate
Show 2 moreShow less
Ianalumab serum concentrations during treatment and follow-up after last dose
Incidence and titer of anti-ianalumab antibodies in serum (ADA assay) over time.
Arms and interventions
Ianalumab monthlyExperimental
Ianalumab s.c. monthly
Ianalumab quarterlyExperimental
Ianalumab s.c. quarterly
Placebo monthlyPlacebo comparator
Placebo s.c. monthly
Drugs: Placebo, Ianalumab
Sites
164 sites in 29 countries
United States 25, China 17, India 11, Japan 11, Brazil 9, Spain 8, Argentina 7, Colombia 6, Mexico 6, Poland 6, Taiwan 6, France 5, Italy 5, South Africa 5, Hungary 4, Thailand 4, Canada 3, Chile 3, Czechia 3, Romania 3, South Korea 3, Bulgaria 2, Germany 2, Guatemala 2, Israel 2, Portugal 2, Slovakia 2, Australia 1, Malaysia 1